Childhood Langerhans Cell Histiocytosis
6
1
1
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
2 terminated out of 6 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Project: Every Child for Younger Patients With Cancer
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia